华大智造2025年净利亏损2.37亿元，同比减亏

Core Insights - The core viewpoint of the article is that BGI Genomics (华大智造) reported a decline in revenue and a net loss for the fiscal year 2025, highlighting challenges in market competition and changes in product sales structure [1] Financial Performance - The company achieved an operating revenue of approximately 2.78 billion yuan, representing a year-on-year decrease of 7.73% [1] - The net profit attributable to shareholders was approximately -237 million yuan, indicating a reduction in losses compared to the previous year [1] Factors Affecting Performance - The decline in revenue and gross profit contribution was primarily due to intensified market competition and a decrease in sales prices of certain products [1] - There was a shift in the sales structure, with an increased proportion of low-throughput gene sequencing products sold [1] Cost Management - Total sales, management, and R&D expenses decreased by approximately 19% year-on-year, attributed to the implementation of measures aimed at improving quality and efficiency [1] - The company focused on enhancing employee productivity, concentrating R&D efforts, and managing marketing expenses throughout the entire cycle, leading to reduced costs compared to the same period last year [1]